In conclusion, the elucidation of the association between NOD1/NOD2-mediated signaling pathways and liver diseases opens new avenues for the development of novel treatments for hepatitis, steatosis, and HCC. This evidence concerns the gene NOD1 and hepatitis A virus infection.